2565.HK
T2PegBio Co., Ltd.
Loading chart…
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-08-25 | PegBio (2565.HK) reported significantly widened interim losses for H1 2026, driven by increased investment in its metabolic disease pipeline and Paidakang commercialization. Despite securing royalty inflows and advancing its lead drug, the market reacted negatively, with the stock underperforming SPY by 1.94% in the two days post-earnings, contradicting the company's positive commercialization messaging. | Earnings Transcript | Neutral | -1.26% (vs SPY: -1.94%) |